Recommendations for observational studies of comorbidity in multiple sclerosis

Neurology

Volumn 86, Issue 15, 2016, Pages 1446-1453

  Marrie, Ruth Ann ^a   Miller, Aaron ^b   Sormani, Maria Pia ^c   Thompson, Alan ^d   Waubant, Emmanuelle ^e   Trojano, Maria ^d   O'Connor, Paul ^f   Fiest, Kirsten ^a   Reider, Nadia ^a   Reingold, Stephen ^g   Cohen, Jeffrey A ^h  

^a UNIVERSITY OF MANITOBA   (Canada)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g Scientific and Clinical Review Associates LLC   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; ANXIETY; AUTOIMMUNE DISEASE; BRAIN ATROPHY; CHRONIC LUNG DISEASE; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DISABILITY; DISEASE DURATION; EMPLOYMENT; ETHNICITY; HEALTH BEHAVIOR; HEALTH CARE UTILIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; MORTALITY; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RACE; RESEARCH PRIORITY; REVIEW; SOCIAL STATUS; COMPLICATION; CONSENSUS DEVELOPMENT; METHODOLOGY; PROCEDURES;

COMORBIDITY; HUMANS; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDIES AS TOPIC; RESEARCH DESIGN;

EID: 84964872986     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002474     Document Type: Review

References (60)

1. Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003;42:1226-1233.
2. Marrie RA, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Mult Scler J 2015;21:263-281.
3. Weinstock-Guttman B, Zivadinov R, Horakova D, et al. Lipid profiles are associated with lesion formation over 24 months in interferon-b treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry 2013; 84:1186-1191.
4. Marrie RA, Miller A, Sormani MP, et al. The challenge of comorbidity in clinical trials for multiple sclerosis. Neurology (in press 2016).
5. Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. Ann Fam Med 2009; 7:357-363.
6. Wingerchuk DM. Smoking: effects on multiple sclerosis susceptibility and disease progression. Ther Adv Neurol Disord 2012;5:13-22.
7. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest 2004;125:27-37.
8. Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 2011;77:573-579.
9. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Does multiple sclerosis-associated disability differ between races? Neurology 2006;66:1235-1240.
10. Marrie RA, Horwitz RI, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology 2009;72:117-124.
11. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain 2006;129:595-605.
12. Akiyama H, Meyer JS, Mortel KF, Terayama Y, Thornby JI, Konno S. Normal human aging: factors contributing to cerebral atrophy. J Neurol Sci 1997;152:39-49.
13. Moran AE, Forouzanfar MH, Roth GA, et al. The global burden of ischemic heart disease in 1990 and 2010: the global burden of disease 2010 study. Circulation 2014; 129:1493-1501.
14. Arnett PA. Longitudinal consistency of the relationship between depression symptoms and cognitive functioning in multiple sclerosis. CNS Spectr 2005;10:372-382.
15. Braley TJ, Segal BM, Chervin RD. Obstructive sleep apnea and fatigue in patients with multiple sclerosis. J Clin Sleep Med 2014;10:155-162.
16. Brass SD, Li CS, Auerbach S. The underdiagnosis of sleep disorders in patients with multiple sclerosis. J Clin Sleep Med 2014;10:1025-1031.
17. Chwastiak LA, Gibbons LE, Ehde DM, et al. Fatigue and psychiatric illness in a large community Sample of persons with multiple sclerosis. J Psychosom Res 2005;59:291-298.
18. Dallmeijer AJ, Beckerman H, de Groot V, van de Port IGL, Lankhorst GJ, Dekker J. Long-term effect of comorbidity on the course of physical functioning in patients after stroke and with multiple sclerosis. J Rehabil Med 2009;41:322-326.
19. DHooghe MB, Haentjens P, Nagels G, De Keyser J. Alcohol, coffee, fish, smoking and disease progression in multiple sclerosis. Eur J Neurol 2012;19:616-624.
20. Durmus H, Kurtuncu M, Tuzun E, et al. Comparative clinical characteristics of early- and adult-onset multiple sclerosis patients with seizures. Acta Neurol Belg 2013; 113:421-426.
21. Egner A, Phillips VL, Vora R, Wiggers E. Depression, fatigue, and health-related quality of life among people with advanced multiple sclerosis: results from an exploratory telerehabilitation study. NeuroRehabilitation 2003;18:125-133.
22. Espinola-Nadurille M, Colin-Piana R, Ramirez- Bermudez J, et al. Mental disorders in Mexican patients with multiple sclerosis. J Neuropsychiatry Clin Neurosci 2010;22:63-69.
23. FinlaysonM, Preissner K, Cho C. Impact of comorbidity on fatigue management intervention outcomes among people with multiple sclerosis. Int J MS Care 2013;15:21-26.
24. Foster M, Zivadinov R, Weinstock-Guttman B, et al. Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis. J Neuroimmunol 2012;243:61-68.
25. Ghajarzadeh M, Sahraian MA, Fateh R, Daneshmand A. Fatigue, depression and sleep disturbances in Iranian patients with multiple sclerosis. Acta Med Iran 2012;50: 244-249.
26. Gottberg K, Einarsson U, Fredrikson S, von Koch L, Holmqvist LW. A population-based study of depressive symptoms in multiple sclerosis in Stockholm county: association with functioning and sense of coherence. J Neurol Neurosurg Psychiatry 2007;78:60-65.
27. Kister I, Caminero A, Monteith T, et al. Migraine is comorbid with multiple sclerosis and associated with a more symptomatic MS course. J Headache Pain 2010;11:417-425.
28. Koch M, Mostert J, Heerings M, Uyttenboogaart M, De Keyser J. Fatigue, depression and disability accumulation in multiple sclerosis: a cross-sectional study. Eur J Neurol 2009;16:348-352.
29. Koch M, Uyttenboogaart M, van Harten A, Heerings M, De Keyser J. Fatigue, depression and progression in multiple sclerosis. Mult Scler 2008;14:815-822.
30. Marrie RA, Cutter G, Tyry T. Substantial adverse association of visual and vascular comorbidities on visual disability in multiple sclerosis. Mult Scler 2011;17:1464-1471.
31. Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010;74:1041-1047.
32. Munteis E, Cano JF, Flores JA, Martinez-Rodriguez JE, Miret M, Roquer J. Prevalence of autoimmune Thyroid disorders in a Spanish multiple sclerosis cohort. Eur J Neurol 2007;14:1048-1052.
33. Oliveira SR, Simao AN, Kallaur AP, et al. Disability in patients with multiple sclerosis: influence of insulin resistance, adiposity, and oxidative stress. Nutrition 2014;30: 268-273.
34. Patten SB, Williams JV, Lavorato DH, Metz LM, Bulloch AG. Disability in a community population with MS with and without mental disorders. Int J Psychiatry Med 2012;43:51-65.
35. Poder K, Ghatavi K, Fisk J, et al. Social anxiety in a multiple sclerosis clinic population. Mult Scler 2009;15: 393-398.
36. Shugaiv E, Tuzun E, Kurtuncu M, et al. Uveitis as a prognostic factor in multiple sclerosis. Mult Scler 2015; 21:105-107.
37. Siepman TA, Janssens AC, de Koning I, Polman CH, Boringa JB, Hintzen RQ. The role of disability and depression in cognitive functioning within 2 years after multiple sclerosis diagnosis. J Neurol 2008;255:910-916.
38. Tettey P, Simpson S Jr, Taylor B, et al. Adverse lipid profile is not associated with relapse risk in MS: results from an observational cohort study. J Neurol Sci 2014; 340:230-232.
39. Tettey P, Simpson S, Taylor B, et al. An adverse lipid profile is associated with disability and progression in disability in people with MS. Mult Scler J 2014;20:1737-1744.
40. Tinghog P, Bjorkenstam C, Carstensen J, et al. Co-morbidities increase the risk of disability pension among MS patients: a population-based nationwide cohort study. BMC Neurol 2014;14:117.
41. Tortorella P, Rocca MA, Colombo B, Annovazzi P, Comi G, Filippi M. Assessment of MRI abnormalities of the brainstem from patients with migraine and multiple sclerosis. J Neurol Sci 2006;244:137-141.
42. Uribe-San-Martin R, Ciampi-Diaz E, Suarez- Hernandez F, Vasquez-Torres M, Godoy-Fernandez J, Carcamo-Rodriguez C. Prevalence of epilepsy in a cohort of patients with multiple sclerosis. Seizure 2014;23:81-83.
43. Weinstock-Guttman B, Zivadinov R, Mahfooz N, et al. Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation 2011;8:127.
44. Weisbrot D, Charvet L, Serafin D, et al. Psychiatric diagnoses and cognitive impairment in pediatric multiple sclerosis. Mult Scler 2014;20:588-593.
45. Wood B, van der Mei I, Ponsonby AL, et al. Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis. Mult Scler J 2013;19:217-224.
46. Zephir H, Gower-Rousseau C, Salleron J, et al. Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease. Mult Scler 2013;20: 1135-1139.
47. Marrie RA, Reider N, Cohen J, et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult Scler J 2015;21:305-317.
48. Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. High frequency of adverse health behaviors in multiple sclerosis. Mult Scler 2009; 15:105-113.
49. Koch M, van Harten A, Uyttenboogaart M, De Keyser J. Cigarette smoking and progression in multiple sclerosis. Neurology 2007;69:1515-1520.
50. Healy BC, Ali EN, Guttmann CRG, et al. Smoking and disease progression in multiple sclerosis. Arch Neurol 2009;66:858-864.
51. Marrie RA, Horwitz RI, Cutter G, Tyry T, Vollmer T. Association between comorbidity and clinical characteristics of MS. Acta Neurol Scand 2011;124:135-141.
52. Lakka H, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-2716.
53. Horton M, Rudick RA, Hara-Cleaver C, Marrie RA. Validation of a self-report comorbidity questionnaire for multiple sclerosis. Neuroepidemiology 2010;35:83-90.
54. Iezzoni LI. Assessing quality using administrative data. Ann Intern Med 1997;127:666-674.
55. Jette N, Quan H, Hemmelgarn B, et al. The development, evolution, and modifications of ICD-10: challenges to the international comparability of morbidity data. Med Care 2010;48:1105-1110.
56. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27.
57. Yurkovich M, Avina-Zubieta JA, Thomas J, Gorenchtein M, Lacaille D. A systematic review identifies valid comorbidity indices derived from administrative health data. J Clin Epidemiol 2015;68:3-14.
58. von Elm E, Altman DG, EggerM, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007;147:573-577.
59. Bennett DA, Brayne C, Feigin VL, et al. Development of the standards of reporting of neurological disorders (STROND) checklist: a guideline for the reporting of incidence and prevalence studies in neuroepidemiology. Eur J Epidemiol 2015;30:569-576.
60. Pohl MA, Blumenthal S, Cordonnier DJ, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 2005;16:3027-3037.